Inozyme 2.82$

Zahlen für Q2/23

• kein Umsatz
  
• Verlust 16 Mio. $
  
• Cash 140 Mio. $
  
• MK 174 Mio. $
  

- expected to fund cash flow requirements into the fourth quarter of 2025

investors.inozyme.com/news-releases/...-financial-results-and

Ein Biotech das man im Auge behalten sollte!

Zahlen für Q3/23

• kein Umsatz
  
• Verlust 17 Mio. $
  
• Cash 192 Mio. $
  
• MK 252 Mio. $
  

– Topline data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in first quarter of 2024

investors.inozyme.com/news-releases/...-financial-results-and

Zahlen für Q1/24

• keine Umsätze
  
• Verlust 23 Mio. $
  
• Cash 166 Mio. $
  
• MK 288 Mio. $
  

- expected to fund operations into the fourth quarter of 2025

https://investors.inozyme.com/news-releases/...-financial-results-and

Zahlen für Q3/24

• keine Umsätze
  
• Verlust 25 Mio. $
  
• Cash 132 Mio. $
  
• MK 196 Mio. $
  

- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024

https://investors.inozyme.com/news-releases/news-release-details/inozyme-pharma-reports-third-quarter-2024-financial-results-and